DHI vs Research Solutions
DHX and RSSS side by side, both in miscellaneous business services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DHX and RSSS compare
DHI is the larger company, worth 2.9 times as much as Research Solutions ($192M against $65.5M).
On earnings, Research Solutions is cheaper: it trades at 21.6× trailing earnings, against 23.3× for DHI.
Research Solutions grew revenue faster over the last twelve months (−1.5% versus −5.0% for DHI).
DHI keeps more of each dollar of sales as profit, with a net margin of 6.3% compared with 5.8% at Research Solutions.
Research Solutions scores higher on the StockData Score (14 against 12 for DHI), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DHX | RSSS |
|---|---|---|
| Size and price | ||
| Market cap | $192M | $65.5M |
| Share price | $4.43 | $1.94 |
| Change, 1 year | 162% | −37.8% |
| Change, 5 years | −14.3% | −19.5% |
| Beta (5Y) | 0.95 | 0.42 |
| Employees | 270 | 141 |
| StockData Score | ||
| Total score | 12 | 14 (better) |
| Valuation score | 6 (better) | 4 |
| Growth score | 0 | 2 (better) |
| Performance score | 3 | 4 (better) |
| Health score | 3 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 23.3× | 21.6× (better) |
| P/S | 1.5× | 1.4× (better) |
| P/B | 2.1× (better) | 3.2× |
| EV/EBITDA | 15.2× | 10.9× (better) |
| P/FCF | 8.6× (better) | 12.5× |
| PEG | – | 0.33 |
| FCF yield | 11.6% (better) | 8.0% |
| Fair value | $6.96 | $2.72 |
| Margin of safety | 36.3% (better) | 28.7% |
| Growth | ||
| Revenue growth (TTM) | −5.0% | −1.5% (better) |
| Revenue growth, 5Y average | 2.8% | 8.8% (better) |
| Net income growth (TTM) | – | 123% |
| EPS growth (TTM) | – | 125% |
| Profitability | ||
| Gross margin | 82.1% (better) | 51.9% |
| Operating margin | 11.6% (better) | 7.4% |
| Net margin | 6.3% (better) | 5.8% |
| FCF margin | 17.9% (better) | 10.8% |
| Return on equity | 8.3% | 16.3% (better) |
| Return on invested capital | 8.4% | 70.1% (better) |
| Financial health | ||
| Debt / equity | 0.32 (better) | 0.00 |
| Net debt / EBITDA | 1.86 | – |
| Interest coverage | 6.1× | – |
| Current ratio | 0.42 | 0.83 (better) |
| Altman Z-score | 2.17 (better) | 2.10 |
| Piotroski F-score | 3 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | 7.6% (better) | 0.08% |
| Shareholder yield | 7.6% (better) | 0.08% |
| Ownership | ||
| Held by institutions | 70.5% | 32.4% |
| Held by insiders | 18.6% | 14.0% |
| Insider net buying, 12 months | −$265K | – |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 0.88% | 0.13% |
Go deeper
- DHX stock overview
- DHX income statement
- DHX valuation and score
- RSSS stock overview
- RSSS income statement
- RSSS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.